|
|
|
 |
|
Office Hours:
Monday - Friday
9am - 5pm
24 hour on-call physician
Telephone:
(858) 637-7888
(619) 582-7888
Fax:
(858) 637-7887
|
|
|
 |
We have an
active clinical trials program associated with
Sharp HealthCare and Scripps Health in the following areas. *Content Updated September 2011
#Note: the embeded links in these below point to the NCI website (which is an external domain.)
Breast Cancer
- Lumpectomy followed by radiation or radiofrequency ablation.
- Taxotere +/- Trio for metastatic breast cancer. NCI study data click here.
- Taxane/Herceptin vs. T-DM1+/-Pertuzumab. NCI study data click here.
- ACOSOG Z1071 axillary node study (surgery).
Leukemia
- Acute Myeloid Leukemia in relapse, cytarabine +/- vosaroxin. NCI study data click here.
- Chronic Lymphocytic Leukemia, 1st line, chlorambucil vs. rituxan/chlorambucil vs. GA101/chlorambucil. NCI study data click here.
Liver Cancer
- Post-TACE, Brivanib vs. placebo. NCI study data click here.
Lung Cancer
- Carbo/gem +/- PARP inhibitor for metastatic squamous cell of lung. NCI study data click here.
- MAGEA3 vaccine after adjuvant chemotherapy for Lung cancer. NCI study data click here.
Lymphoma
- R-CHOP +/- Velcade for newly diagnose DLCL. NCI study data click here.
- Bendamustine +/- GA101 for rituxan resistant low grade lymphoma. NIC study data click here.
- Ofatumumab vs. rituxan for 2nd line low grade lymphoma. NCI study data click here.
Myelofibrosis
- Jak-2 + Myelofibrosis, Ruxolitinib. NCI study data click here.
Ovarian Cancer
- Carbo/taxol every 3 weeks vs. carbo/ taxol (weekly) for 1st line stage 4 ovarian cancer. NCI study data click here.
- Doxil +/- EC145 for platinum resistant ovarian cancer. NCI study data click here.
Prostate Cancer
- HRPC – MDV3100 vs. placebo. NCI study data click here.
- Taxotere/prednisone +/- custirsen (antisense oligonucleotide) for stage 4 prostate cancer. NCI study data click here.
Solid Tumor
- Any Her-2 positive, stage 4 disease – tax/carbo/herceptin. NCI study data click here.
|
|
|
|
|
